Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
E7386 in Selected Advanced Neoplasms
NCT03264664Phase 1Active, not recruiting
- Sponsor
- Eisai Co., Ltd.
- Start
- Jul 2017
- Primary completion
- Mar 2027
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 1, open-label, single-arm trial of e7386 in advanced neoplasm, sponsored by Eisai Co., Ltd. Primary endpoints: Dose-limiting Toxicities at 28 days, Recommended Phase 2 Dose at 28 days and 1 more. Started Jul 2017; status: active, not recruiting.
02
Drugs
e7386
03
Conditions
advanced neoplasm
Beyond the preview
Go deeper on NCT03264664.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03264664.